方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| UHDRS：统一亨廷顿病评定量表× | AIMS: 非自主运动量表× | |
|---|---|---|
| 领域 | 神经病学 | 神经病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1996 | 1976 |
| 提出者≠ | Huntington Study Group | National Institute of Mental Health |
| 类型≠ | Clinician-rated and performance-based | Clinician-rated observation |
| 开创性文献≠ | Huntington Study Group (1996). Unified Huntington's Disease Rating Scale: Reliability and consistency. Movement Disorders, 11(2), 136-142. link ↗ | National Institute of Mental Health (1976). Abnormal Involuntary Movement Scale (AIMS). In: Rockland, L. H., Schooler, N. R., & Levine, J. (Eds.), Drug Treatment of Mental Disorders. New York: Raven Press. link ↗ |
| 别名≠ | UHDRS, Huntington's Rating Scale | AIMS |
| 相关≠ | 4 | 3 |
| 摘要≠ | The Unified Huntington's Disease Rating Scale (UHDRS) is the comprehensive, multidomain assessment instrument for Huntington's disease, a neurodegenerative disorder caused by expanded CAG trinucleotide repeats. Developed by the Huntington Study Group in 1996, the UHDRS measures motor, cognitive, functional, and psychiatric manifestations of disease. The UHDRS is the gold-standard outcome measure in Huntington's disease clinical trials and longitudinal natural history studies. | The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating scale for assessing tardive dyskinesia, a iatrogenic movement disorder resulting from chronic antipsychotic medication exposure. Developed by the National Institute of Mental Health in 1976, the 12-item scale systematically measures involuntary movements across facial, oral, limb, and trunk regions. The AIMS is mandatory screening tool for patients on long-term antipsychotic therapy and essential for monitoring antipsychotic-associated movement complications. |
| ScholarGate数据集 ↗ |
|
|